Rabbit Recombinant Monoclonal CD19 antibody - conjugated to Alexa Fluor® 594.
IgG
Rabbit
Alexa Fluor® 594
Ex: 590nm, Em: 617nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).
B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19
Rabbit Recombinant Monoclonal CD19 antibody - conjugated to Alexa Fluor® 594.
B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19
IgG
Rabbit
Alexa Fluor® 594
Ex: 590nm, Em: 617nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
SP110
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This supplementary information is collated from multiple sources and compiled automatically.
CD19 is a transmembrane protein also known as B4 or B-lymphocyte antigen CD19 with an approximate molecular weight of 95 kDa. It is expressed on the surface of B cells throughout their development from pro-B cells to mature B cells. CD19 functions mechanically as a coreceptor enhancing the sensitivity of B cell receptor (BCR) signaling. This protein plays a significant role in promoting the activation and proliferation of B cells by lowering the threshold for antigen receptor engagement.
CD19 acts as an essential player in B cell signaling. CD19 integrates signals from the BCR with other coreceptors acting as a signaling hub. It participates in forming a signaling complex that includes proteins like CD21 and CD81 which further amplifies BCR-mediated signaling. This complex plays a critical role in B cell activation differentiation and survival ensuring that immune responses are efficiently mounted against pathogens.
The CD19 protein fits into key immune response pathways such as the BCR signaling pathway and the PI3K-Akt signaling pathway. CD19 collaborates with other proteins like CD21 CD81 and PI3K within these pathways. Its interaction in the PI3K-Akt pathway for instance supports critical processes including B cell activation and homeostasis contributing to the adaptive immune response.
CD19 is connected to B cell malignancies and autoimmune diseases. B cell acute lymphoblastic leukemia (ALL) often shows aberrant CD19 expression making it a valuable target for therapeutic interventions like anti-CD19 monoclonal antibodies. Additionally overexpression or mutations of CD19 may contribute to autoimmune diseases by disrupting normal B cell regulation. CD19's connection with proteins like CD22 and CD20 in these pathological contexts highlights its relevance in developing targeted therapies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com